59237-49-9

Basic information

• Product Name: Methyl 6-Methoxy-5-nitronicotinate
• Synonyms: Methyl 6-Methoxy-5-nitronicotinate
• CAS NO: 59237-49-9
• Molecular Formula: C8H8N2O5
• Molecular Weight: 212.15952
• Mol File: 59237-49-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 331.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.356±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.67±0.20(Predicted)
• CAS DataBase Reference: Methyl 6-Methoxy-5-nitronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-Methoxy-5-nitronicotinate(59237-49-9)
• EPA Substance Registry System: Methyl 6-Methoxy-5-nitronicotinate(59237-49-9)

Safety Data

• Hazardous Substances Data: 59237-49-9(Hazardous Substances Data)

Usage

General Description

Methyl 6-Methoxy-5-nitronicotinate, as a chemical compound, does not have extensive information readily available such as its physical and chemical properties, possible applications, or detailed uses. With a specific CAS number of 15736-79-7, this specialized nicotinic acid derivative could potentially be useful in chemical research or various industrial applications. However, since information is limited, one would need to conduct further detailed research or consultation with a specialist to gain comprehensive knowledge about Methyl 6-Methoxy-5-nitronicotinate. It is always advisable when dealing with less-known chemicals to use appropriate care and precaution measures.

Upstream product

• 59237-53-5 methyl 6-chloro-5-nitro-pyridine-3-carboxylate 
• 124-41-4 sodium methylate 
• 6635-31-0 6-hydroxy-5-nitronicotinic acid 

Downstream Products

• 1211532-25-0 6-methoxy-5-nitronicotinaldehyde 
• 166742-23-0 methyl 5-amino-6-(methylthio)nicotinate 
• 59237-50-2 methyl 5-amino-6-methoxy-nicotinate 

Relevant articles and documents

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Compounds as PDE IV and TNF inhibitors

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.